A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Recruiting

Phase 3

Baxdrostat & DapagliflozinA Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Sponsor:

AstraZeneca

Code:

NCT06268873

Conditions

Chronic Kidney Disease and Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Baxdrostat/dapagliflozin

Dapagliflozin in combination with placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-04-13.